Literature DB >> 19656127

CCR5 is required for regulation of alloreactive T-cell responses to single class II MHC-mismatched murine cardiac grafts.

T Nozaki1, J M Rosenblum, A D Schenk, D Ishii, R L Fairchild.   

Abstract

The effector CD4 T-cell response in wild-type C57BL/6 recipients of single class II MHC-disparate B6.H-2(bm12) cardiac allografts is restricted by CD4(+)CD25(+) regulatory T cells (Tregs) resulting in long-term allograft survival. To investigate the role chemokine receptors might play in Treg function, this study tested the requirement for CCR5 on Tregs to suppress the alloimmune response in C57BL/6 recipients of B6.H-2(bm12) cardiac allografts. In contrast to the long-term survival of B6.H-2(bm12) allografts in wild-type recipients (>100 days), the allografts were acutely rejected within 25 days in CCR5(-/-) recipients with intense infiltration of CD4 T cells. Numbers and duration of donor-reactive CD4 T cells producing IFN-gamma and IL-4 were markedly increased in spleens of B6.CCR5(-/-) versus wild-type recipients. Wild-type and B6.CCR5(-/-) mice had equivalent numbers of splenic FoxP3(+) Tregs before and following transplantation, and these Tregs were equivalently suppressive in vitro. However, diminished numbers of FoxP3(+) Tregs infiltrated B6.H-2(bm12) allografts in B6.CCR5(-/-) recipients. Adoptive transfer of wild-type, but not CCR5-deficient, CD4(+)CD25(+) Tregs to CCR5(-/-) recipients restored long-term survival of B6.H-2(bm12) cardiac grafts. Collectively, these results indicate that CCR5 expression is required for the regulatory functions of Tregs that restrict alloreactive CD4 T-cell responses to single class II MHC-mismatched cardiac allografts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656127      PMCID: PMC2760830          DOI: 10.1111/j.1600-6143.2009.02786.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  37 in total

1.  Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.

Authors:  Marc A Gavin; Sally R Clarke; Ella Negrou; Alena Gallegos; Alexander Rudensky
Journal:  Nat Immunol       Date:  2001-12-10       Impact factor: 25.606

Review 2.  Chemokines: directing leukocyte infiltration into allografts.

Authors:  Tarek el-Sawy; Nader M Fahmy; Robert L Fairchild
Journal:  Curr Opin Immunol       Date:  2002-10       Impact factor: 7.486

3.  Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection.

Authors:  Gabriel T Schnickel; Sam Bastani; George R Hsieh; Ali Shefizadeh; Rubina Bhatia; Michael C Fishbein; John Belperio; Abbas Ardehali
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

4.  Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility-disparate skin grafts.

Authors:  Y Watarai; S Koga; D R Paolone; T M Engeman; C Tannenbaum; T A Hamilton; R L Fairchild
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

5.  Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance.

Authors:  S Gregori; M Casorati; S Amuchastegui; S Smiroldo; A M Davalli; L Adorini
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

6.  Beneficial effects of targeting CCR5 in allograft recipients.

Authors:  W Gao; K L Faia; V Csizmadia; S T Smiley; D Soler; J A King; T M Danoff; W W Hancock
Journal:  Transplantation       Date:  2001-10-15       Impact factor: 4.939

7.  Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size.

Authors:  Masayuki Sho; Akira Yamada; Nader Najafian; Alan D Salama; Hiroshi Harada; Sigrid E Sandner; Alberto Sanchez-Fueyo; Xin Xiao Zheng; Terry B Strom; Mohamed H Sayegh
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Mechanisms underlying blockade of allograft acceptance by TLR ligands.

Authors:  Paige M Porrett; Xueli Yuan; David F LaRosa; Patrick T Walsh; Jaeseok Yang; Wenda Gao; Peiying Li; Jidong Zhang; Javeed M Ansari; Wayne W Hancock; Mohamed H Sayegh; Maria Koulmanda; Terry B Strom; Laurence A Turka
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

9.  Identification of regulatory T cells in tolerated allografts.

Authors:  Luis Graca; Stephen P Cobbold; Herman Waldmann
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

10.  Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes.

Authors:  Francesco Annunziato; Lorenzo Cosmi; Francesco Liotta; Elena Lazzeri; Roberto Manetti; Vittorio Vanini; Paola Romagnani; Enrico Maggi; Sergio Romagnani
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  5 in total

1.  Peripherally circulating CD4⁺ FOXP3⁺ CXCR3⁺ T regulatory cells correlate with renal allograft function.

Authors:  A Hoerning; S Köhler; C Jun; B Tebbe; J Fu; J Menke; B Wilde; S Dolff; T Feldkamp; D M Briscoe; A Kribben; P F Hoyer; O Witzke
Journal:  Scand J Immunol       Date:  2012-09       Impact factor: 3.487

2.  Novel CD8 T cell alloreactivities in CCR5-deficient recipients of class II MHC disparate kidney grafts.

Authors:  Daisuke Ishii; Joshua M Rosenblum; Taiji Nozaki; Austin D Schenk; Kiyoshi Setoguchi; Charles A Su; Victoria Gorbacheva; William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

3.  Antibody-mediated rejection of single class I MHC-disparate cardiac allografts.

Authors:  Y Hattori; R P Bucy; Y Kubota; W M Baldwin; R L Fairchild
Journal:  Am J Transplant       Date:  2012-05-11       Impact factor: 8.086

4.  Experimental glomerular endothelial injury in vivo.

Authors:  George Haddad; Lin Fu Zhu; David C Rayner; Allan G Murray
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

Review 5.  Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.

Authors:  Catherine Edmunds; Udeme D Ekong
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.